Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)

Report Summary Clinical trials market now witness a paradigm shift. Naïve heterogeneous patient populations in the developing nations is opening up new avenues for the clinical trials market. Developing countries also offer faster go to market which is triggering major pharmaceutical companies to direct their investment in these regions. Apart from this, stringent regulations and tight R&D budgets in the Pharma-Biotech industry are also forcing companies to move to east. This scenario has further boosted the alliances between the pharma-biotech companies and the clinical research organizations, with the latter accounting for major chunk of the trials conducted Browse all : Market Research Reports Today, emerging countries account for the largest share of the phase II/III (prime stages) clinical trials conducted globally with major focus on oncology, Alzheimer’s, metabolic and cardiovascular diseases. Support from the respective government bodies is one of the major factors affecting the clinical trials market. Clinical trials sponsored by the industry have a much higher share in the market as compared to government organizations.rnThe key players (Clinical Research Organizations) in the market include Chiltern, Omnicare, PPD, Parexel, Kendle and Quintles. This research report categorizes the Global Clinical Trials Market on the basis of phases, indications, and study design analyzing trends in each. Each section will provide market data, market drivers, trends and opportunities, key players, and competitive outlook. This report will also provide more than 20 company profiles. Table of Contentsrn1 Introductionrn2 Executive Summaryrn3 Market Overviewrn4 Clinical Trials Market, by Typesrn5 Geographic Analysisrn6 Competitive Landscapern7 Company ProfilesrnLIST OF TABLES Related Reports: Clinical Trial Recruitment in Dermatology - Most Trials Focus on Atopic Dermatitis While Acne Vulgaris Has Highest Patient Numbers Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value